Utsumi, Tomohiro
Yoshiike, Takuya
Kaneita, Yoshitaka
Aritake-Okada, Sayaka
Matsui, Kentaro
Nagao, Kentaro
Saitoh, Kaori
Otsuki, Rei
Shigeta, Masahiro
Suzuki, Masahiro
Kuriyama, Kenichi
Funding for this research was provided by:
The Ministry of Health, Labor and Welfare, Government of Japan (#19FA1009)
Article History
Received: 25 June 2022
Accepted: 10 October 2022
First Online: 4 November 2022
Competing interests
: Dr. Utsumi reports payments for lectures outside the submitted work, including services at speakers bureaus from Eisai. Dr. Yoshiike reports payments for lectures outside the submitted work, including services at speakers bureaus from MSD and Takeda Pharmaceutical. Dr. Kaneita has no relevant conflicts of interest to declare. Dr. Aritake-Okada reports several items outside the submitted work, namely expert testimony from Idorsia Pharma, grants from the Kao Corporation, payments for lectures, including services at speakers bureaus from MSD, as well as services at speakers bureaus and payments for the development of educational presentations from Takeda Pharmaceutical and payments for the development of educational presentations from NIHON SOYAKU. Dr. Matsui reports payments for lectures outside the submitted work, including services at speakers bureaus from Eisai, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Yoshitomi Pharmaceutical. Dr. Nagao reports payments for lectures outside the submitted work, including services at speakers bureaus from Takeda Pharmaceutical and Sumitomo Dainippon Pharm. Dr. Saitoh reports personal fees received from Yoshitomi Pharmaceutical outside the submitted work. Dr. Otsuki reports no relevant conflicts of interest. Dr. Shigeta has no relevant conflicts of interest to declare. Dr. Suzuki reports grants and payments for lectures outside the submitted work, including services at speakers bureaus from Dainippon Sumitomo, Eisai, Mochida Pharmaceutical, Otsuka Pharmaceutical, and Takeda Pharmaceutical, grants from Novartis, and payments for lectures and services at speakers bureaus from EA Pharma, Meiji Seika Pharma, MSD, Pfizer, Yoshitomi Pharmaceutical, and Viatris. Dr. Kuriyama reports items outside the submitted work, including grants from Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, Shionogi Pharma, and Pfizer, as well as grants and personal fees from Meiji Seika Pharma, Eisai, MSD, Takeda Pharmaceutical, Tsumura, and Eli Lilly, and personal fees from Yoshitomi Pharmaceutical and Sumitomo Pharma. There are no other disclosures to report including non-financial interest.